Orlistat weight-loss drugs

Xenical - Alli - THLP - tetrahydrolipstatin - orlistat



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - prevention in all type of patients - prevention in people with impaired glucose tolerance

Heymsfield, 2000orlistatplacebo675 (359/316) Confirmatory
XENDOS (Chiasson), 2002orlistatplacebo1429 (714/715) Confirmatory -

Obesity and overweight - All mechanism in all type of patients

Bakris, 2002Orlistatplacebo554 (278/276)
Broom, 2002Orlistatplacebo526 (265/261)
Broom,, 2001Orlistatplacebo142 (71/71)
Davidson, 1999Orlistatplacebo892 (668/224)
Deerochanawong,, 2001Orlistatplacebo252 (126/126)
Derosa, 2003Orlistatplacebo50 (27/23)
Gotfredsen, 2001Orlistatplacebo30 (16/14)
Halpern, 2003Orlistatplacebo343 (169/174)
Hanefeld, 2002Orlistatplacebo383 (195/188)
Hauptman, 2000Orlistatplacebo422 (210/212)
Hill, 1999Orlistatplacebo369 (181/188)
Hollander, 1998Orlistatplacebo322 (163/159)
Karhunen, 2000Orlistatplacebo72 (36/36)
Kelley, 2002Orlistatplacebo550 (274/276)
Krempf, 2005Orlistatplacebo696 (346/350)
Lindgarde, 2000Orlistatplacebo376 (190/186)
Lucas, 2003Orlistatplacebo444 (256/188)
Micic, 1999Orlistatplacebo119 (60/59)
Miles, 2002Orlistatplacebo516 (255/261)
Muls, 2001Orlistatplacebo294 (147/147)
Naumov, 2002Orlistatplacebo30 (15/15)
Reaven, 2001Orlistatplacebo247 (156/91)
Rissanen, 2001Orlistatplacebo51 (25/26)
Rosenfalck, 2002Orlistatplacebo4 (3/1)
Rossner, 2000Orlistatplacebo487 (244/243)
Shi Yi, 2001Orlistatplacebo1128 (986/142)
Sjostrom, 1998Orlistatplacebo688 (345/343)
Vidgren, 1999Orlistatplacebo75 (37/38)